Kane Biotech Inc. (KNE.V)
CAD 0.09
(-5.26%)
CAD 0.09
(-5.26%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -3.35 Million CAD | 0.19% |
| 2022 | -3.36 Million CAD | 31.12% |
| 2021 | -4.88 Million CAD | -15.6% |
| 2020 | -4.22 Million CAD | -17.66% |
| 2019 | -3.59 Million CAD | -12.94% |
| 2018 | -3.17 Million CAD | -17.95% |
| 2017 | -2.69 Million CAD | -10.7% |
| 2016 | -2.43 Million CAD | -50.99% |
| 2015 | -1.61 Million CAD | -5.87% |
| 2014 | -1.52 Million CAD | -4.99% |
| 2013 | -1.45 Million CAD | 0.91% |
| 2012 | -1.46 Million CAD | -18.51% |
| 2011 | -1.23 Million CAD | -26.06% |
| 2010 | -979.92 Thousand CAD | -10.86% |
| 2009 | -883.89 Thousand CAD | 11.35% |
| 2008 | -997.05 Thousand CAD | 3.68% |
| 2007 | -1.03 Million CAD | -19.19% |
| 2006 | -868.48 Thousand CAD | 16.1% |
| 2005 | -1.03 Million CAD | -71.79% |
| 2004 | -602.56 Thousand CAD | -48.58% |
| 2003 | -405.54 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -1.23 Million CAD | -19.3% |
| 2024 Q2 | -1.1 Million CAD | 10.4% |
| 2023 FY | -3.82 Million CAD | -13.65% |
| 2023 Q1 | -1.01 Million CAD | -83.47% |
| 2023 Q2 | -535.72 Thousand CAD | 47.26% |
| 2023 Q4 | -1.03 Million CAD | 13.87% |
| 2023 Q3 | -1.19 Million CAD | -123.6% |
| 2022 Q3 | -851.59 Thousand CAD | -17.93% |
| 2022 Q4 | -553.64 Thousand CAD | 34.99% |
| 2022 Q2 | -722.09 Thousand CAD | 41.6% |
| 2022 Q1 | -1.23 Million CAD | 5.13% |
| 2022 FY | -3.36 Million CAD | 31.12% |
| 2021 Q1 | -983.73 Thousand CAD | 7.7% |
| 2021 Q3 | -1.58 Million CAD | -57.89% |
| 2021 Q4 | -1.3 Million CAD | 18.01% |
| 2021 Q2 | -1 Million CAD | -2.35% |
| 2021 FY | -4.88 Million CAD | -15.6% |
| 2020 Q2 | -595.87 Thousand CAD | 58.76% |
| 2020 Q4 | -1.06 Million CAD | 4.67% |
| 2020 Q3 | -1.11 Million CAD | -87.62% |
| 2020 Q1 | -1.44 Million CAD | -18.26% |
| 2020 FY | -4.22 Million CAD | -17.66% |
| 2019 Q2 | -953.47 Thousand CAD | -53.97% |
| 2019 Q3 | -795.73 Thousand CAD | 16.54% |
| 2019 Q4 | -1.22 Million CAD | -53.53% |
| 2019 FY | -3.59 Million CAD | -12.94% |
| 2019 Q1 | -619.27 Thousand CAD | 6.52% |
| 2018 Q4 | -662.47 Thousand CAD | 28.55% |
| 2018 Q1 | -889.06 Thousand CAD | -0.07% |
| 2018 Q2 | -700.06 Thousand CAD | 21.26% |
| 2018 FY | -3.17 Million CAD | -17.95% |
| 2018 Q3 | -927.23 Thousand CAD | -32.45% |
| 2017 Q4 | -888.43 Thousand CAD | -2.83% |
| 2017 FY | -2.69 Million CAD | -10.7% |
| 2017 Q3 | -863.98 Thousand CAD | -18.12% |
| 2017 Q1 | -211.12 Thousand CAD | 55.68% |
| 2017 Q2 | -731.41 Thousand CAD | -246.45% |
| 2016 FY | -2.43 Million CAD | -50.99% |
| 2016 Q4 | -476.37 Thousand CAD | 20.28% |
| 2016 Q2 | -831.31 Thousand CAD | -57.06% |
| 2016 Q3 | -597.52 Thousand CAD | 28.12% |
| 2016 Q1 | -529.3 Thousand CAD | -15.92% |
| 2015 Q2 | -308.83 Thousand CAD | 33.36% |
| 2015 Q4 | -456.61 Thousand CAD | -19.07% |
| 2015 FY | -1.61 Million CAD | -5.87% |
| 2015 Q3 | -383.49 Thousand CAD | -24.18% |
| 2015 Q1 | -463.43 Thousand CAD | -8.3% |
| 2014 Q4 | -427.9 Thousand CAD | -34.8% |
| 2014 Q1 | -288.5 Thousand CAD | -140.09% |
| 2014 Q3 | -317.44 Thousand CAD | 35.1% |
| 2014 Q2 | -489.13 Thousand CAD | -69.54% |
| 2014 FY | -1.52 Million CAD | -4.99% |
| 2013 Q3 | -331.27 Thousand CAD | -0.52% |
| 2013 Q1 | -669.62 Thousand CAD | -62.5% |
| 2013 FY | -1.45 Million CAD | 0.91% |
| 2013 Q4 | -120.16 Thousand CAD | 63.73% |
| 2013 Q2 | -329.55 Thousand CAD | 50.79% |
| 2012 Q1 | -309.66 Thousand CAD | -2.33% |
| 2012 Q3 | -391.98 Thousand CAD | -11.93% |
| 2012 Q4 | -412.06 Thousand CAD | -5.12% |
| 2012 FY | -1.46 Million CAD | -18.51% |
| 2012 Q2 | -350.18 Thousand CAD | -13.09% |
| 2011 Q1 | -354.73 Thousand CAD | -79.79% |
| 2011 FY | -1.23 Million CAD | -26.06% |
| 2011 Q3 | -349.19 Thousand CAD | -52.68% |
| 2011 Q2 | -228.71 Thousand CAD | 35.53% |
| 2011 Q4 | -302.6 Thousand CAD | 13.34% |
| 2010 Q2 | -184.33 Thousand CAD | 34.18% |
| 2010 Q1 | -280.06 Thousand CAD | -163.18% |
| 2010 Q4 | -197.3 Thousand CAD | 25.33% |
| 2010 Q3 | -264.23 Thousand CAD | -43.35% |
| 2010 FY | -979.92 Thousand CAD | -10.86% |
| 2009 FY | -883.89 Thousand CAD | 11.35% |
| 2009 Q1 | -206.09 Thousand CAD | -75.44% |
| 2009 Q4 | -106.41 Thousand CAD | 65.51% |
| 2009 Q2 | -235.74 Thousand CAD | -14.39% |
| 2009 Q3 | -308.56 Thousand CAD | -30.89% |
| 2008 Q1 | -212.55 Thousand CAD | 25.67% |
| 2008 FY | -997.05 Thousand CAD | 3.68% |
| 2008 Q4 | -117.46 Thousand CAD | 68.51% |
| 2008 Q3 | -372.99 Thousand CAD | -5.91% |
| 2008 Q2 | -352.17 Thousand CAD | -65.68% |
| 2007 Q1 | -194.44 Thousand CAD | 27.06% |
| 2007 Q2 | -382.3 Thousand CAD | -96.61% |
| 2007 FY | -1.03 Million CAD | -19.19% |
| 2007 Q3 | -172.27 Thousand CAD | 54.94% |
| 2007 Q4 | -285.96 Thousand CAD | -65.99% |
| 2006 Q2 | -242.91 Thousand CAD | -51.86% |
| 2006 FY | -868.48 Thousand CAD | 16.1% |
| 2006 Q1 | -159.95 Thousand CAD | 44.05% |
| 2006 Q4 | -266.6 Thousand CAD | -32.03% |
| 2006 Q3 | -201.93 Thousand CAD | 16.87% |
| 2005 Q4 | -285.87 Thousand CAD | -10.15% |
| 2005 Q1 | -209.93 Thousand CAD | 11.57% |
| 2005 Q2 | -270.93 Thousand CAD | -29.06% |
| 2005 Q3 | -259.52 Thousand CAD | 4.21% |
| 2005 FY | -1.03 Million CAD | -71.79% |
| 2004 Q4 | -237.39 Thousand CAD | -139.4% |
| 2004 Q3 | -99.16 Thousand CAD | 33.2% |
| 2004 Q2 | -148.46 Thousand CAD | -38.7% |
| 2004 FY | -602.56 Thousand CAD | -48.58% |
| 2004 Q1 | -107.03 Thousand CAD | -111.74% |
| 2003 Q2 | -24.18 Thousand CAD | 0.0% |
| 2003 Q3 | -174.86 Thousand CAD | -623.02% |
| 2003 FY | -405.54 Thousand CAD | 0.0% |
| 2003 Q4 | -50.54 Thousand CAD | 71.09% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Arch Biopartners Inc. | -3.35 Million CAD | -0.066% |
| Covalon Technologies Ltd. | -4.48 Million CAD | 25.211% |
| Hemostemix Inc. | -2.33 Million CAD | -43.875% |
| Universal Ibogaine Inc. | 497.15 Thousand CAD | 775.325% |
| MedMira Inc. | -1.94 Million CAD | -72.677% |
| Marvel Biosciences Corp. | -2.31 Million CAD | -44.782% |
| NervGen Pharma Corp. | -17.77 Million CAD | 81.114% |
| XORTX Therapeutics Inc. | -6.38 Million CAD | 47.392% |